MICHAEL BELIN: Open Payments
NPI 1114564028 · BENTON, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$23,131 in 59 payments from 6 companies in 2025. Trend: 2023 $962 · 2024 $5,055 · 2025 $23,131
Honoraria: $17,731Travel & lodging: $4,078Food & beverage: $1,322
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 48 | $22,798 |
| Neurocrine BioSciences, Inc. | 1 | $117 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Janssen Pharmaceuticals, Inc | 3 | $64 |
| Vanda Pharmaceuticals Inc. | 2 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
Products named: Qelbree, INGREZZA, REXULTI, INVEGA SUSTENNA, FANAPT, HETLIOZ, CAPLYTA.
Industry payments across AR — which companies pay providers there.
